在阿尔茨海默氏病中,APOE4 影响中性粒细胞-微细胞交叉
Eleonora Terrabuio1, Gabriela Constantin2
1Department of Medicine, University of Verona, Strada le Grazie 8, 37134 Verona, Italy.
Trends in immunology
|September 25, 2024
概括
称为中性粒细胞的免疫细胞可以通过阻断女性APOE4载体中有益的微质来加剧阿尔茨海默病 (AD). 针对中性粒细胞中介素-17 (IL-17) 或APOE4的向改善了大脑免疫力,并减少了小鼠的疾病症状.
科学领域:
- 神经免疫学 神经免疫学
- 阿尔茨海默氏症疾病的发病因子
- 细胞免疫学 细胞免疫学
背景情况:
- 循环免疫细胞在阿尔茨海默病 (AD) 发病过程中起作用,但它们的具体功能尚不清楚.
- 以前的研究表明,免疫细胞活动和AD进展之间存在联系,特别是在具有APOE4基因型的个体中.
研究的目的:
- 在阿尔茨海默氏病 (AD) 的背景下,研究特定免疫细胞的作用,即中性粒细胞的介素-17 (IL-17) +.
- 探索这些中性粒细胞对神经保护性微质细胞的影响,特别是在女性APOE4载体中.
- 评估针对AD治疗中性粒细胞中IL-17信号或APOE4的治疗潜力.
主要方法:
- 在AD的背景下识别IL-17+中性粒细胞的特定子集.
- 评估这些中性粒细胞对微质细胞功能的抑制作用.
- 在中性粒细胞中试验阻断IL-17信号传递.
- 中性粒细胞中APOE4的遗传删除.
- 在小鼠模型中评估微质反应和粉样蛋白病理学.
主要成果:
- 确定了一组IL-17+中性粒细胞,该中性粒细胞可以积极抑制神经保护性微质细胞.
- 这种抑制作用在女性APOE4载体中尤为明显.
- 阻止中性粒细胞中IL-17信号传递恢复了微质功能.
- 从中性粒细胞中删除APOE4也改善了微质功能障碍.
- 中性粒细胞中的IL-17阻断和APOE4删除都导致了小鼠粉样蛋白病理的减少.
结论:
- 干白素-17 (IL-17) 中性粒细胞代表一个关键的细胞参与者,通过损害微质细胞,促进阿尔茨海默氏症 (AD) 病原发生.
- 针对中性粒细胞内的IL-17信号或APOE4提供了一个有希望的治疗策略,以恢复神经保护和减少AD中的粉样蛋白负担.
- 这些发现强调了性别和遗传背景 (APOE4) 在免疫介导的AD病理学中的重要性.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
08:47Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions
Published on: July 26, 2024
1.9K
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
